BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
KRChoksey Research Report
Dr. Reddy's Laboratories Ltd. posted strong growth in consolidated revenue in FY22, driven by a rise in base business volume and new product launches.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
Geographically, the revenue growth was largely influenced by strong growth across markets such as India, the U.S., Russia, and others. U.S. generics business crossed the $1.0 billion mark in FY22, driven by high-value launches such as gVascepa or Icosapent Ethyl soft gel and gVascostrict or Vasopressin injections (first authorised generic to launch) and enhancement in volume share of the existing products, which more than offset the price erosion.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
Dr. Reddy's Russia revenue grew at 32.0% YoY in FY22, driven by improved performance of the base business, the launch of new products, and divestment income from the sale of a few non-core brands such as Ciprolet and Levolet for Rs 1.77 billion in Q4 FY22.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
